News Channels

13 Jul 2018 Oyster Point Pharma Announces Positive Results from Phase 2 Clinical Trial of the Company’s Investigational Treatment for Dry Eye Disease
13 Jul 2018 Landos Biopharma Initiates Phase 1 Clinical Trial of BT-11, an Oral LANCL2 Agonist for Treatment of IBD
13 Jul 2018 Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
13 Jul 2018 Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
13 Jul 2018 CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China
13 Jul 2018 Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC
13 Jul 2018 Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
13 Jul 2018 Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
13 Jul 2018 Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
13 Jul 2018 CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH
13 Jul 2018 Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA
13 Jul 2018 Termination of License and Development Agreement for "OBLEAN® Tablets 120mg" for Treatment of Obesity
12 Jul 2018 Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
12 Jul 2018 Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant
12 Jul 2018 Moderna Provides Mid-Year Corporate Update
12 Jul 2018 Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-Generation Antibody-Based Therapeutics into the Clinic
12 Jul 2018 Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
12 Jul 2018 AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program
12 Jul 2018 FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
12 Jul 2018 Aurigene Announces First in Human Dosing with RoRγt Inverse Agonist AUR-101

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up